Atlas One · Host Biology · Scale 07 — System

Gastric Cancer

HER2 overexpression (~15-20%) and MSI-H (~10-15%) define actionable subsets; pembrolizumab is first-line for PD-L1+ gastric cancer; trastuzumab+chemotherapy is standard for HER2+ disease; ramucirumab (VEGFR2) and zolbetuximab (CLDN18.2) are approved in later lines.

Also known as: gastric cancer, stomach cancer, gastric adenocarcinoma, GEJ cancer, gastroesophageal junction cancer, gastric carcinoma, GC

Scale 07 — SystemScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
gastric-cancer

Gastric Cancer

HER2 overexpression (~15-20%) and MSI-H (~10-15%) define actionable subsets; pembrolizumab is first-line for PD-L1+ gastric cancer; trastuzumab+chemotherapy is standard for HER2+ disease; ramucirumab (VEGFR2) and zolbetuximab (CLDN18.2) are approved in later lines.

Entry Metadata

FieldValue
IDgastric-cancer
NameGastric Cancer
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toHer2 connects-toVegf connects-toPd 1 connects-toEgfr connects-toHelicobacter Pylori connects-toEpstein Barr Virus connects-toHereditary Diffuse Gastric Cancer connects-toCholangiocarcinoma connects-toStomach connects-toEsophageal Cancer connects-toColorectal Cancer connects-toLynch Syndrome connects-toIron Deficiency Anemia

Sources